PDS Biotechnology Corp.

As of June 11, 2025, PDS Biotechnology Corp. exhibits a neutral technical stance with a sideways trend, showing mixed signals across indicators, including mildly bullish MACD and KST on weekly but bearish on monthly, while daily moving averages are mildly bearish.

As of March 2022, the management team of PDS Biotechnology Corp. includes Independent Chairman Mr. Stephen Glover, President and CEO Dr. Frank Bedu-Addo, Directors Dr. Otis Brawley, Dr. Ilian Iliev, and Independent Directors Ms. Kamil Ali-Jackson, Mr. DeLyle Bloomquist, and Mr. Gregory Freitag.

PDS Biotechnology Corp. is an immuno-oncology company developing clinical-stage immunotherapies for cancer, classified as a micro-cap with a market cap of $74.05 million and a recent net profit loss of $8 million. The company has no dividend yield and negative return metrics.

As of Jun 18, PDS Biotechnology Corp. has a market capitalization of 74.05 million and reported net sales of 0.00 million with a net profit of -35.50 million over the last four quarters. The balance sheet shows shareholder's funds of 19.00 million and total assets of 45.36 million.